Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
WEDNESDAY, Oct. 4, 2023 (HealthDay News) -- For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published online Oct. 2 in Nature Medicine.
Matthew D. Galsky, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a phase 2 study of 76 patients with MIBC who received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients who achieved a clinical complete response (cCR) could proceed without cystectomy.
Of the patients, 33 achieved a cCR (43 percent); 32 of the 33 opted to forgo immediate cystectomy. The researchers found that the positive predictive value of cCR for a composite outcome of two-year metastasis-free survival in patients forgoing immediate cystectomy or
"Treatment for muscle-invasive bladder cancer is in need of major improvements from both a quality-of-life and an effectiveness standpoint," Galsky said in a statement. "If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer."
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Related Posts
FDA Gives OK to Merck’s Antiviral At-Home COVID Pill
THURSDAY, Dec. 23, 2021 (HealthDay News) -- Many Americans now have two oral...
American Urological Association, April 28-May 1
The annual meeting of the American Urological Association was held from April...
Repeated Low-Level Red-Light Intervention Prevents Myopia in Children
WEDNESDAY, April 26, 2023 (HealthDay News) -- A repeated low-level, red-light...
Dangerous Infections in ‘Preemie’ Babies May Begin in the Gut
THURSDAY, May 4, 2023 (HealthDay News) -- About half of extremely preterm babies...